Department of Clinical and Experimental Medicine, Pharmacology Section and LTTA Centre, University of Ferrara, Ferrara, Italy.
Neuropsychopharmacology. 2012 Jul;37(8):1856-66. doi: 10.1038/npp.2012.33. Epub 2012 Mar 28.
Recent in vitro results suggest that cocaine may exert direct and/or indirect allosteric enhancing actions at dopamine (DA) D(2) receptors (D(2)Rs). In the present paper we tested the hypothesis that cocaine in vivo can enhance the effects of the D(2)-likeR agonist quinpirole in rats by using microdialysis and pharmacological behavioral studies. Furthermore, in vitro D(2)-likeR binding characteristics and Gα(i/o)-protein coupling, in the absence and in the presence of cocaine, have been investigated in rat striatal membranes. Intra-nucleus accumbens perfusion of the D(2)-likeR agonist quinpirole (10 μM) reduced local dialysate glutamate levels, whereas cocaine (10 and 100 nM) was ineffective. At a low concentration (100 nM), cocaine significantly enhanced quinpirole-induced reduction of accumbal extracellular glutamate levels. The behavioral experiments showed that cocaine (0.625 mg/kg), but not the DA uptake blocker GBR 12783 (1.25 mg/kg), enhanced quinpirole (1 mg/kg)-induced hyperlocomotion. Finally, cocaine (100 nM), but not GBR 12783 (200 nM), produced a small, but significant increase in the efficacy of DA to stimulate binding of GTPγS to striatal D(2)-likeRs, whereas the D(2)-likeR binding characteristics were unchanged in striatal membranes by cocaine in the nM range. The significant increase in the maximal response to DA-stimulated GTPγS binding to D(2)-likeRs by 100 nM cocaine remained in the presence of GBR 12783. The observed cocaine-induced enhancement of the Gα(i/o)-protein coupling of D(2)Rs may be in part because of allosteric direct and/or indirect enhancing effects of cocaine at these receptors. These novel actions of cocaine may have relevance for understanding the actions of cocaine upon accumbal DA, and/or glutamate transmission and thus its rewarding as well as relapsing effects.
最近的体外研究结果表明,可卡因可能在体内直接和/或间接通过变构增强多巴胺(DA)D2 受体(D2R)的作用。在本文中,我们通过微透析和药理学行为研究测试了可卡因在体内是否可以增强 D2 样受体激动剂喹吡罗的作用的假设。此外,还研究了在不存在和存在可卡因的情况下,大鼠纹状体膜中 D2 样受体的结合特性和 Gα(i/o)-蛋白偶联。在伏隔核内灌注 D2 样受体激动剂喹吡罗(10μM)可降低局部透析液谷氨酸水平,而可卡因(10 和 100nM)无效。在低浓度(100nM)下,可卡因可显著增强喹吡罗诱导的伏隔核细胞外谷氨酸水平降低。行为实验表明,可卡因(0.625mg/kg),而不是 DA 摄取阻滞剂 GBR 12783(1.25mg/kg),可增强喹吡罗(1mg/kg)诱导的过度活跃。最后,可卡因(100nM),而不是 GBR 12783(200nM),可使 DA 刺激 GTPγS 与纹状体 D2 样受体结合的效力略有增加,但在纳摩尔范围内,可卡因对纹状体膜中 D2 样受体的结合特性没有改变。在 GBR 12783 存在的情况下,100nM 可卡因对 DA 刺激 GTPγS 与 D2 样受体结合的最大反应的显著增加仍然存在。可卡因诱导的 D2 受体 Gα(i/o)-蛋白偶联增强可能部分归因于可卡因对这些受体的变构直接和/或间接增强作用。可卡因的这些新作用可能与理解可卡因对伏隔核 DA 以及谷氨酸传递的作用及其奖励和复发作用有关。